Other · developed by Sanofi Aventis Us
Enoxaparin is a low molecular weight heparin, a synthetic anticoagulant that acts with a higher ratio of anti-Factor Xa to anti-Factor IIa activity. It is studied in venous thromboembolism, deep venous thrombosis, pulmonary embolism and metastatic pancreatic cancer.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 28, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01828697 | Phase 4 | Deep Venous Thrombosis | Completed | ASPE |
| NCT07015905 | Phase 3 | Venous Thromboembolism (VTE) | Recruiting | REGN |
| NCT01839487 | Phase 2 | Metastatic Pancreatic Cancer | Completed | HALO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Venous Thromboembolism (VTE)Deep Venous ThrombosisMetastatic Pancreatic CancerPulmonary Embolism
Updated Nov 8, 2026.